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Abstract
Background: We sought to characterize the temporal trends in nasopharyngeal carriage of macrolide-resistant
pneumococci during a period with increased heptavalent pneumococcal conjugate vaccine (PCV7) coverage in
Central Greece.
Methods: Streptococcus pneumoniae isolates were recovered from 2649 nasopharyngeal samples obtained from
day-care center attendees in Central Greece during 2005–2009. A phenotypic and genotypic analysis of the isolates
was performed, including the identification of macrolide resistance genes mef(A), subclasses mef(A) and mef(E),
as well as erm(B).
Results: Of the 1105 typeable S. pneumoniae isolates, 265 (24%) were macrolide-resistant; 22% in 2005, 33.3% in
2006, 23.7% in 2007, and 20.5% in 2009 (P=0.398). Among these macrolide-resistant pneumococci, 28.5% possessed
erm(B), 24.3% erm(B)+mef(E), 41.8% mef(E), and 5.3% mef(A). A mef gene as the sole resistance determinant was
carried by 31% of macrolide-resistant isolates belonging to PCV7 serotypes and 75.8% of the non-PCV7 serotypes.
Across the 4 annual surveillances, pneumococci carrying mef(A) gradually disappeared, whereas serotype 19F isolates
carrying both erm(B) and mef(E) persisted without significant yearly fluctuations. Among isolates belonging to
non-PCV7 serotypes, macrolide-resistance was observed in those of serotypes 6A, 19A, 10A, 15A, 15B/C, 35F, 35A,
and 24F. In 2009, ie 5 years after the introduction of PCV7 in our country, 59% of macrolide-resistant pneumococci
belonged to non-PCV7 serotypes.
Conclusions: Across the study period, the annual frequency of macrolide-resistant isolates did not change
significantly, but in 2009 a marked shift to non-PCV7 serotypes occurred. Overall, more than half of the
macrolide-resistant isolates possessed erm(B) either alone or in combination with mef(E). erm(B) dominated among
isolates belonging to PCV7 serotypes, but not among those of non-PCV7 serotypes.
Background
Streptococcus pneumoniae is a gram-positive bacterium
commonly found in the human nasopharynx, in partic-
ular during early childhood [1,2]. In most individuals
colonization is asymptomatic and does not evolve into
disease [3,4]. In addition to the carriage state, S. pneumoniae
is also a common human pathogen responsible for
bacteremia, sepsis, and meningitis, as well as noninvasive
disease, such as non-bacteremic pneumonia, otitis media,
and sinusitis [4,5].
Resistance to erythromycin and other macrolides is
common in S. pneumoniae isolates recovered from car-
riers and patients [6-14]. The major mechanisms of
macrolide resistance in S. pneumoniae are target modi-
fication and drug efflux [15]. The genetic determinant
conferring macrolide resistance by target modification is
mainly erm(B) [16]. The erm(B) gene methylates the pep-
tidyl transferase center of 23S rRNA, thereby conferring
high-level resistance to 14-, 15- and 16-membered ring
macrolides, lincosamides and streptogramin B (MLSB
phenotype) [15].
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The second macrolide resistance mechanism is an
efflux pump system encoded by mef and an ATP-binding
cassette protein encoded by the mel gene [17]. The efflux
mechanism confers resistance to 14- and 15-member
macrolides only (M phenotype) [18,19]. Two main var-
iants of mef, mef(E) and mef(A), which are approximately
90% identical at the nucleotide level and have been
assigned to the same class of macrolide resistance deter-
minants, mef(A) [20], are found in S. pneumoniae
[21,22]. These two genes are located on different genetic
elements [22,23]. mef(A) is located on the defective trans-
poson Tn1207.1 [24], or the closely related Tn1207.3 [25],
whereas mef(E) on “mega” element [17,26,27].
Greece has a high prevalence of antibiotic-resistant
S. pneumoniae [28-30]. In our country, PCV7 became
available in October 2004; it was officially introduced to
children younger than 5 years of age in January 2006 and
was reimbursed by 80% by the national health insurance
system in June 2006. The aim of the present investigation
was to study trends in carriage of macrolide-resistant
pneumococci and to analyze their antibiotic susceptibil-
ity, serotypes, and macrolide resistance determinants.
The isolates were collected in a prospective study con-
ducted among day-care center attendees in Central Greece
between 2005 and 2009.
Methods
Study population
Nasopharyngeal specimens were obtained from children
attending day-care centers in Larissa, Volos, Trikala, and
Karditsa, the 4 largest cities of Central Greece during an
approximately three-month period in 2005, 2006, 2007,
and 2009. In the annual surveillance, 1 sample was obtained
from each child. Information regarding the participant’s
PCV7 vaccination status was collected. The research
protocol was approved by the Ethics Committee of the
General University Hospital of Larissa. Informed consent
was obtained from one of the parents of each attendee.
Vaccine schedule
The Hellenic National Committee for Immunization Pro-
grams recommends PCV7 for routine administration as
a 4-dose series for infants at 2, 4, 6, and 12 to 18 months
of age. Catch-up immunization is recommended for all
children up to 59 months of age [31].
Laboratory procedures
Specimens of nasopharyngeal secretions were obtained
pernasally using sterile swabs on flexible shafts with cal-
cium alginate fiber tips (Fisher Scientific, Pittsburgh,
Philadelphia, USA). Swabs were placed in Amies trans-
port medium (TGV, Sanofi Diagnostic Pasteur, Marne la
Coquette, France) after sampling and were transferred
to the Laboratory of the Division of Pediatric Infectious
Disease of the University of Thessaly, where isolation, iden-
tification and susceptibility testing of the S. pneumoniae
isolates were performed as previously described [32].
The maximum delay between collection and cultivation
was 7h.
The swabs were plated onto Columbia agar plates sup-
plemented with 5% defibrinated horse blood, 10 μg of
colistin sulfate and 15 μg of nalidixic acid per milliliter.
The plates were incubated at 35°C in an atmosphere sup-
plemented with 5% CO2 for 24–72 h. Phenotypic char-
acteristics (morphology and α-hemolysis) were used for
the presumptive identification of pneumococci. Pneu-
mococcal identification was confirmed by optochin sus-
ceptibility and bile solubility assays. When suspected
pneumococcal colonies with more than one morphology
were observed, each type was purified for further testing.
Susceptibility testing to various antimicrobial agents
representing different classes of antibiotics was performed
on Mueller-Hinton agar supplemented with 5% defibri-
nated horse blood, as follows. S. pneumoniae isolates
were tested for susceptibility to erythromycin and clin-
damycin by both the disk diffusion method and the
E-test method (AB Biodisk, Solna, Sweden). Isolates were
screened for penicillin resistance using 1 μg oxacillin
disks. If the oxacillin inhibition zone was <20 mm,
minimal inhibitory concentration (MIC) to penicillin was
determined by the E-test method. Susceptibility to quino-
lones was determined by the E-test method. Isolates were
tested with levofloxacin except for isolates recovered in
2005 that were tested with ciprofloxacin. Finally, suscep-
tibility to chloramphenicol, tetracycline, and trimethoprim-
sulfamethoxazole (TMP-SMZ) was determined by the
disk diffusion method. For susceptibility testing, plates
with the antibiotic disks and E-test strips were incu-
bated in 5% CO2. The susceptibility breakpoints of the
Clinical and Laboratory Standards Institute (CLSI) [33]
and the European Committee on Antimicrobial Testing
(EUCAST) [34] were used to classify organisms as sus-
ceptible, intermediate or resistant to the studied anti-
biotics. The oral penicillin V susceptibility breakpoints
of CLSI were applied since in pediatric infections the
treatment is mainly oral: ≤0.06 μg/ml, susceptible; 0.12–
1 μg/ml, intermediate; and ≥2 μg/ml, resistant. The
benzylpenicillin susceptibility breakpoints of EUCAST for
infections other than meningitis were used: ≤0.06 μg/ml,
susceptible; 0.12–2 μg/ml, intermediate; and >2 μg/ml,
resistant. Pneumococci were defined as resistant to cipro-
floxacin if their ciprofloxacin MICs were ≥4 μg/ml.
An isolate was defined as multidrug resistant (MDR)
when it was resistant to ≥3 antibiotic classes. Penicillins,
cephalosporins, and carbapenems were considered a
single class.
The macrolide resistance phenotypes were determined
on the basis of the pattern of susceptibility to erythromycin
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and clindamycin and confirmed by the double disk diffu-
sion test using erythromycin and clindamycin disks (BBL,
Cockeysville, MD). Specifically, 15 μg erythromycin and
2 μg clindamycin disks were placed 16 mm apart. Induc-
tion was present when the zone of inhibition around the
clindamycin disk was blunted on the side next to the
erythromycin disk.
Detection and analysis of the erm(B) and mef genes
Bacterial DNA was extracted by using the QIAamp DNA
Mini kit (QIAGEN, Hilden, Germany). The presence of
macrolide resistance genes was detected by PCR as
described previously [35]. In summary, we amplified the
genes by PCR and analyzed the amplified DNA products
by agarose gel electrophoresis. For erm(B) we used the pri-
mer pair 5’-CGA GTG AAA AAG TAC TCA ACC-3’ and
5’-GGC GTG TTT CAT TGC TTG ATG-3’ [36] and formef
gene the primer pair 5’-GCGTTTAAGATAAGCTGGCA-3’
and 5’-CCTGCACCATTTGCTCCTAC-3’ [22]. In order to
discriminate between mef(A), subclasses mef(A) and mef(E),
PCR restriction fragment length polymorphism analysis
was performed, as suggested by Oster et al. [21]. The
1743-bp PCR product was digested with the BamHI or
the DraI restriction enzyme. In mef(A) there is one BamHI
site, so restriction generates two fragments of 1,340 and
403 bp, while in mef(E) there are no BamHI restriction
sites. Restriction of mef(A) with DraI yields two frage-
ments of 1,493 and 250 bp, respectively, while restriction
of mef(E) yields three fragments of 782, 711, and 250 bp.
Capsule serotyping
Serotype determination of pneumococci, including sero-
type 6C, was performed at our Laboratory in Larissa by
using Pneumotest-Latex and by the capsular swelling
method using pneumococcal type/group and/or factor
antisera from Statens Serum Institut (SSI, Copenhagen,
Denmark). We followed the SSI guidelines for serotyping.
Statistical analysis
An attendee was defined as age-appropriately vaccinated
if at sampling the child had received all the PCV7 doses
recommended for the age at initiation of immuniza-
tion [37]. A dose of PCV7 vaccine was counted if it had
been received at least 30 days before the sampling date.
Pneumococcal isolates were classified as PCV7 serotypes,
non-PCV7 serotypes and nontypeable.
To assess the 4 groups of attendees enrolled during
the 2005, 2006, 2007, and 2009 surveillance, categorical
parameters were compared using the χ2 for trend. For
the assessment of 2 groups, categorical parameters were
compared using 2-sided Fisher exact test. The statistical
analysis was performed using SPSS version 13.0. An effect
was considered significant when P<0.05.
Results
Population and samples
Between February 28, 2005 and May 19, 2009, cultures
were obtained from 2649 children aged 13 to 76 months
(median age: 48 months). There were no children younger
than 13 months old attending the studied day-care
centers. The characteristics of children at the time of
sampling are presented in Table 1. Description of the
day-care centers has been published previously [8,30].
Of the 2649 children, 1196 (45.1%) were identified as
carriers of S. pneumoniae. Forty-six attendees carried two
different pneumococcal isolates. Of the totally 1242 pneu-
mococcal isolates, 1105 (89%) were typeable. The present
analysis was based on this collection of typeable isolates.
Carriage of macrolide-resistant pneumococci
From 2005 to 2009, 265 (24%) of the 1105 typeable
S. pneumoniae isolates were macrolide-resistant. Across
the 4 surveillance periods, the proportion of macrolide-
resistant isolates did not change significantly. Specifi-
cally, their frequencies were 22% (77 of 350) in 2005,
33.3% (64 of 192) in 2006, 23.7% (63 of 266) in 2007, and
20.5% (61 of 297) in 2009 (P=0.398). However, across the
4 sampling periods a significant decrease was noted in
macrolide-resistant isolates belonging to PCV7 serotypes
(from 17.4% to 26%, 12% and 8.4%; P<0.001) and a sig-
nificant increase in the proportion of macrolide-resistant
isolates belonging to non-PCV7 serotypes (from 4.6% to
7.3%, 11.7% and 12.1%; P<0.001) (Figure 1).
Among macrolide-resistant pneumococci, the propor-
tion of isolates belonging to non-PCV7 serotypes was
20.8% (16 of 77) in 2005, 21.9% (14 of 64) in 2006, 49.2%
(31 of 63) in 2007, and 59% (36 of 61) in 2009 (P<0.001).
During the first 2 annual surveillances, PCV7 serotypes
19F, 23F, 14, and 6B accounted for 60 (77.9%) of the 77
macrolide-resistant isolates in 2005 and 50 (78.1%) of the
64 in 2006. In contrast, during the 2009 surveillance,
it was non-PCV7 serotypes 6A, 19A, 15A, and 15B/C that
accounted for 33 (54.1%) of the 61 macrolide-resistant
pneumococci.
Macrolide resistance determinants, phenotypes,
and co-resistance
Of the 265 macrolide-resistant pneumococci, 263 were
studied for the presence of macrolide resistance determi-
nants (Table 2). Seventy-five (28.5%) carried the erm(B)
gene, 64 (24.3%) the erm(B)+mef(E) genes, 110 (41.8%)
mef(E), and 14 (5.3%) mef(A) (Table 2). All mef(A)- or
mef(E)-positive S. pneumoniae isolates exhibited the
M-phenotype. All erm(B)- and dual erm(B)+mef(E)-positive
isolates showed the constitutive MLSB phenotype.
MICs to erythromycin of mef(A)-positive isolates ranged
from 8 to 64 μg/ml (MIC50=32 μg/ml; MIC90=64 μg/ml),
mef(E)-positive from 1 to 64 μg/ml (MIC50=4 μg/ml;
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MIC90=8 μg/ml), erm(B)-positive from 4 to 256 μg/ml
(MIC50=256 μg/ml; MIC90=256 μg/ml), and dual
erm(B)+mef(E)-positive was 256 μg/ml (MIC90=256 μg/ml).
A significant decline in mef(A) isolates was noted
across the study period (Figure 2). Specifically,
mef(A)-positive pneumococci of PCV7 serotypes ac-
counted for 10.4% of the macrolide-resistant isolates in
2005, 1.6% in 2006, and 0% in 2007 and 2009 (P<0.001),
whereas mef(A)-positive isolates of non-PCV7 serotypes
accounted for 0% of the macrolide-resistant isolates
in 2005, 4.7% in 2006, 3.2% in 2007, and 0% in 2009
(P=0.993) (Figure 3).
Initially, the mef(E) gene was common among isolates
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Figure 1 Serotype distribution of macrolide-resistant
nasopharyngeal pneumococcal isolates and percentage of
attendees age-appropriately vaccinated with PCV7 at the time
of surveillance.
Table 1 Characteristics of children at the time of enrollment (N=2649)
Characteristic Year of surveillance P
2005 2006 2007 2009
Time-period of enrollment February 28 to June 7 February 2 to April 13 February 26 to May 17 February 24 to May 19
PCV7 in the National Immunization
Program
– + + +
PCV7 reimbursed – – + +
No. of enrolled children 769 494 566 820
Age, median (range), months 49 (15–76) 46.5 (13–70) 46 (13–73) 48 (14–72) —
Male gender 417 (54.2)a 248 (50.2) 297 (52.5) 427 (52.1) 0.529
Antibiotic use in the preceding 3 months 433/764b (56.7) 260/489 (53.2) 284/566 (50.2) 459/818 (56.1) 0.647
Vaccinated with ≥1 dose of PCV7 99 (12.9) 161 (32.6) 397 (70.1) 783 (95.5) <0.001
Age-appropriately vaccinated 92 (12) 150 (30.4) 351 (62) 668 (81.5) <0.001
Streptococcus pneumoniae carriage
per age-group, months
13 − 23 12/21 (57.1) 11/22 (50) 18/26 (69.2) 13/18 (72.2) 0.176
24 – 35 74/121 (61.2) 34/69 (49.3) 50/99 (50.5) 43/100 (43) 0.01
36 – 47 130/231 (56.3) 78/185 (42.2) 84/183 (45.9) 118/279 (42.3) 0.006
48 – 59 101/240 (42.1) 70/188 (37.2) 109/208 (52.4) 132/349 (37.8) 0.721
≥60 53/156 (34) 13/30 (43.3) 25/50 (50) 28/74 (37.8) 0.273
Overall 370 (48.1) 206 (41.7) 286 (50.5) 334 (40.7) 0.036
aNumber in parentheses is percent, unless otherwise indicated.
bThe denominator indicates the number of children with available information on recent antibiotic use.





erm(B) erm(B)+mef(E) mef(E) mef(A)
6A 69 0 0 64 (92.8) 5 (7.2)
6B 12 11 (91.7)a 0 1 (8.3) 0
9V 1 0 0 1 (100) 0
10A 5 5 (100) 0 0 0
14 17 8 (47.1) 0 0 9 (52.9)
15A 3 3 (100) 0 0 0
15B 3 3 (100) 0 0 0
15C 1 1 (100) 0 0 0
19A 8 7 (87.5) 0 1 (12.5) 0
19F 108 3 (2.8) 64 (59.3) 41 (38) 0
23F 30 30 (100) 0 0 0
24F 1 1 (100) 0 0 0
35A 2 0 0 2 (100) 0
35F 3 3 (100) 0 0 0
aNumber in parentheses, percent.
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among pneumococci of non-PCV7 ones (Figure 3). Spe-
cifically, mef(E)-positive isolates belonging to PCV7 sero-
types accounted for 19.5% of the macrolide-resistant
isolates in 2005, 28.1% in 2006, 6.3% in 2007, and 10.2%
in 2009 (P=0.018), while mef(E)-positive pneumococci
belonging to non-PCV7 serotypes accounted for 11.7%
of the macrolide-resistant isolates in 2005, 17.2% in 2006,
41.3% in 2007, and 35.6% in 2009 (P<0.001).
The erm(B) gene was common initially, from 2005
through 2007, among isolates belonging to PCV7 sero-
types and in 2009 among those of non-PCV7 serotypes
(Figure 3). Specifically, erm(B)-positive isolates belonging
to PCV7 serotypes accounted for 20.8% of the macrolide-
resistant isolates in 2005, 32.8% in 2006, 23.8% in 2007,
and 0% in 2009 (P=0.003), while erm(B)-positive isolates of
non-PCV7 serotypes accounted for 9.1% of the macrolide-
resistant pneumococci in 2005, 0% in 2006, 4.8% in 2007,
and 22% in 2009 (P=0.013).
The erm(B)+mef(E)-positive isolates belonged to serotype
19F (Table 2) and accounted for 28.6% of the macrolide-
resistant isolates in 2005, 15.6% in 2006, 20.6% in 2007,
and 32.2% in 2009 (P=0.638) (Figure 4).
Among the macrolide-resistant pneumococcal isolates
recovered in 2005 and 2006, 53.9% carried the erm(B)
gene alone or in combination with mef(E). In 2009, 54.2%
of the macrolide-resistant isolates possessed erm(B) alone
or in combination with mef(E) (Figure 2).
Co-resistance rates among the 263 isolates with
molecular evaluation are presented in Table 3. According
to both CLSI and EUCAST breakpoints, nonsusceptibility
to one or more other antimicrobial agents was found in
248 (94.3%) of the 263 erythromycin-resistant isolates,
constituting 16 different resistance patterns. Of these 248
isolates, 92.3% were nonsusceptible to penicillin, 70.2%
(CLSI breakpoints) and 68.5% (EUCAST breakpoints) to
TMP-SMZ, 63.7% to tetracycline, 56% to clindamycin and
16.9% to chloramphenicol.
Multidrug-resistance was significantly more frequent
among isolates carrying erm(B), either alone or in combi-
nation with mef(E), than among isolates harboring mef(E)
or mef(A) alone (P<0.001) (Table 3). Pneumococci pos-
sessing erm(B) expressed a total of 11 different resistance
patterns. Macrolide-resistant serotype 14 isolates har-
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Figure 2 Frequencies of macrolide resistance determinants according to the year of surveillance.
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Figure 3 Frequencies of macrolide resistance determinants among isolates belonging to PCV7 and non-PCV7 serotypes according to
the year of surveillance.
Grivea et al. BMC Infectious Diseases 2012, 12:255 Page 5 of 9
http://www.biomedcentral.com/1471-2334/12/255
(MICs 1–2 μg/ml; MIC90=2 μg/ml) were found in the
2006 surveillance in 3 day-care centers. Finally, isolates
carrying either mef(E) or mef(A) expressed five different
resistance patterns.
Fourteen macrolide-resistant isolates had an MIC to
penicillin of 4 μg/ml; 12 (18.8%) of the 64 isolates with
erm(B)+mef(E) and 2 (1.8%) of the 110 mef(E)-positive
pneumococci (Table 3).
Of the 265 macrolide-resistant pneumococcal isolates,
188 were tested with levofloxacin and all of them were
found to be susceptible (MICs 0.25–1 μg/ml; MIC50=
0.5 μg/ml; MIC90=1 μg/ml). Among the remainder 77
isolates tested with ciprofloxacin, we did not identify any
ciprofloxacin-resistant isolates. These 77 pneumococci
had ciprofloxacin MICs from 0.25 to 1 μg/ml (MIC50=
1 μg/ml; MIC90=1 μg/ml).
Discussion
In Greece, an increase in the rate of macrolide resistance
among S. pneumoniae occurred after the introduction
of newer macrolides in the 1990s and their extensive use
thereafter. We have published the phenotypical and mo-
lecular analysis of the macrolide-resistant pneumococci
recovered from young carriers in different geographic loca-
tions of Greece between 1995 and 1999 [32,38,39]. The
overall rate of macrolide-resistant S. pneumoniae naso-
pharyngeal isolates was 18%, while these isolates belonged
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Figure 4 Serotype specific macrolide resistance determinants according to the year of surveillance.
Table 3 Co-resistance among macrolide-resistant isolates of Streptococcus pneumoniae, 2005-2009
Antibiotic nonsusceptibility erm(B) erm(B)+mef(E) mef(E) mef(A)
(n=75) (n=64) (n=110) (n=14)
CLSI EUCAST CLSI EUCAST CLSI EUCAST CLSI/EUCAST
Penicillin-nonsusceptible
MIC50/90 (MIC range) 1/2 (0.125-2) 2/4 (0.25-4) 0.25/2 (0.125-4)
Intermediate 43 (57.3)a,b 58 (77.3)c 21 (32.8) 52 (81.2) 85 (77.3) 105 (95.5) 0
Resistant 15 (20) 0 43 (67.2) 12 (18.8) 22 (20) 2 (1.8) 0
Clindamycin 75 (100) 75 (100) 64 (100) 64 (100) 0 0 0
Tetracycline 55 (73.3) 55 (73.3) 63 (98.4) 63 (98.4) 40 (36.4) 40 (36.4) 0
Chloramphenicol 41 (54.7) 41 (54.7) 1 (1.6) 1 (1.6) 0 0 0
TMP-SMZ 62 (82.7) 61 (81.3) 64 (100) 64 (100) 48 (43.6) 45 (40.9) 0
MDR 74 (98.7) 73 (97.3) 64 (100) 64 (100) 48 (43.6) 46 (41.8) 0
aNumber in parentheses is percent, unless otherwise indicated.
bOral penicillin V breakpoints.
cBenzylpenicillin breakpoints (infections other than meningitis).
TMP-SMZ: trimethoprim-sulfamethoxazole; MDR: multidrug-resistant.
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decreasing frequency). Subsequently, studies on clinical
as well as colonizing isolates from Greece [R] have
reported significantly higher rates of macrolide resistance
(up to ~50%) than that found in our initial studies
[28,29,40]. The highest rate of macrolide resistance has
been reported in pneumococci recovered from children
with non-invasive infections, particularly acute otitis
media [28].
Across the 4 surveillance periods of the present study
and in parallel to an increase in the number of children
who were immunized with PCV7, the frequency of the
macrolide-resistant isolates did not change significantly.
Overall, 24% of the typeable S. pneumoniae isolates were
macrolide-resistant. This result is in line with a study on
carriage among day-care attendees in Lisbon [41]. How-
ever, in 2009 a major shift in the serotype distribution of
macrolide-resistant isolates occurred. Macrolide-resistant
isolates of non-PCV7 serotypes replaced those belong-
ing to PCV7 ones. This shift is in accordance with a
recent French study [7]. Vaccination against 7 serotypes
of S. pneumoniae has led to the near extinction of vac-
cine serotypes in both asymptomatic carriage and disease
[7,11,41]. In carriage, vaccine serotypes have been replaced
by nonvaccine serotypes. Clonal expansion and/or sero-
type switching contribute to this replacement [42].
Overall, more than half (52.9%) of our macrolide-
resistant isolates possessed erm(B) either alone or in
combination with mef(E). A significant association was
found between PCV7 serotypes and the presence of erm
(B), either alone or in combination with mef(E) on the
one hand and non-PCV7 serotypes and a mef gene as the
sole resistance determinant on the other. Among pneu-
moccoci harboring a mef gene as the sole resistance de-
terminant, the ratio of mef(E)- to mef(A)-positive isolates
was 7.9:1. This ratio was significantly reversed from the
one that we observed among carriers during 1995–1999,
which was 1:2.3 [39], and the 1:5 ratio reported from
Germany during 2005–2006 [23].
As an overall concept, drug efflux mediated by mef
genes has been the most common mechanism in strains
of S. pneumoniae in North America, whereas in most of
the European countries and the Far East, the prevalent
mechanism has been rRNA methylation encoded by erm
(B) [9]. Nevertheless, this pattern of macrolide resistance
determinants is not static and may be changing due to
clonal spread of S. pneumoniae of certain serotypes and
horizontal transfer of mef elements among streptococci
[23,43]. Actually, in recent papers, mef(A) was the pre-
dominant macrolide resistance determinant in Norway
(2001–2005) [44] and Germany (2005–2006) [23], whereas
increased frequency of erm(B) as well as of the dual combin-
ation was found in the United States (2005–2008) [13,45].
In the pre-PCV7 period, pneumococci of serotype 14
contributed significantly to macrolide resistance. Among
children, serotype 14 had a higher frequency in invasive
disease than observed in carriage and non-invasive dis-
ease [28]. We have previously reported the circulation of
mef(A)-positive macrolide-resistant, penicillin-susceptible
serotype 14 isolates with a genotype identical to the
international clone England-914 among young carriers in
Greece [39]. Similar isolates continued to circulate in our
area during the first 2 years of the present study. In
addition, in 2006 we found macrolide-resistant serotype
14 isolates possessing erm(B) and exhibiting penicillin-
nonsusceptibility. Following the immunization with PCV7,
a rapid decrease in the circulation of serotype 14 was
noted and it is no longer a major macrolide-resistant
serotype in Greece as well as in other countries [46,47].
This study reports a high frequency of serotype 19F
pneumococci with both erm(B) and mef(E) recovered from
carriers in several day-care centers in Central Greece
across all sampling periods. Since 2001, isolates with
the dual resistance mechanism have been increasingly
reported from many parts of the world [13,23,45,48-50].
They have mainly been isolated from carriers or patients
with non-invasive disease, particularly acute otitis media
[45,50]. Worldwide, most isolates with the dual resistance
mechanism belong to serotypes 19F or 19A [45,48].
Although serotype 19F is represented in the PCV7
vaccine, it affords low levels of protection against upper
respiratory infections such as acute otitis media [51] and
has been shown to be the least immunogenic of the vac-
cine serotypes [52]. Moreover, little evidence shows that
19F provides cross-protection against serotype 19A. In
Greece, antibiotic pressure may have also contributed
to the persistence of these MDR isolates. In our country,
isolates with the dual resistance mechanism in a low
frequency were identified for the first time among car-
riers in Athens during 2003 [29]. In the present study,
which differentiated between mef(A) subclasses mef(A)
and mef(E), only isolates carrying the mef(E) gene, but
not mef(A), with erm(B) were observed, underscoring the
different genetic background of mef(E) and mef(A). Our
findings are in line with a recent study from the USA
[45]. S. pneumoniae isolates possessing the mef(A) sub-
class mef(A) gene, carried on transposon Tn1207.1, in
combination with erm(B) have been described in a paper
from Australia [53].
Conclusions
From 2005 to 2009, the annual rate of macrolide-
resistant colonizing isolates did not change significantly.
Overall, more than half (52.9%) of the macrolide-
resistant isolates harbored the erm(B) gene either alone
or in combination with mef(E). Multidrug resistance was
significantly more common among the S. pneumoniae
isolates carrying erm(B) than among those possessing the
mef(E) gene as the single macrolide resistance determinant.
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Across the 4 sampling periods, the circulation of isolates
possessing the mef(A) gene gradually disappeared. Marked
changes were observed in the most recent surveillance,
as the PCV7 coverage increased. In 2009, a shift to
macrolide-resistant pneumoccoci belonging to non-PCV7
serotypes was noted. Serotypes 6A, 19A, 15A, and 15B/C
accounted for 54.1% of macrolide-resistant pneumoccoci.
Further trends in the carriage of macrolide resistance
determinants among pneumococci belonging to non-
PCV7 serotypes in the post-PCV7 period remain to be
addressed by future surveillance studies.
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